Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

War Of Words Back Between Taro, Sun Pharma; Both Vow to Wrest Taro Control

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The battle for control of Israeli generic drug maker Taro is set to heat up further as Indian drug maker Sun Pharmaceuticals and Taro separately vowed their resolve to retain and acquire control of the beleaguered company
Advertisement

Related Content

Advantage Sun Pharma As Tel Aviv Court Rules Out Special Tender Offer For Taro Shares
Advantage Sun Pharma As Tel Aviv Court Rules Out Special Tender Offer For Taro Shares
Sun Clears FTC Hurdle For Taro Acquisition; Sells Carbamezapine To Fellow Indian Co. Torrent
Sun Clears FTC Hurdle For Taro Acquisition; Sells Carbamezapine To Fellow Indian Co. Torrent
Sun Pharma Extends Offer For Taro Shares In Ongoing Rocky Affair
India’s Sun Pharma To Pursue Taro Merger As Q4 Profits Surge On U.S. Protonix Sales
India’s Sun Pharma To Pursue Taro Merger As Q4 Profits Surge On U.S. Protonix Sales
Advertisement
UsernamePublicRestriction

Register

SC069144

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel